Vaylen vs HealthRX
Two GLP-1 desks, one scoreboard. We put Vaylen and HealthRX head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Vaylen takes this head-to-head.
Vaylen scores 87 to 86 on our six-factor Brief Score — A full-service, LegitScript-certified desk pairing brand access and an oral route with nationwide reach at a fair mid price.
That doesn't make HealthRX a bad call — it's best for readers who want an accredited, physician-supervised program with a needle-free oral tablet option on either molecule — and value a legitscript trust signal, while accepting that some tiers are company-stated. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Vaylen | HealthRX | |
|---|---|---|
| Brief Score | 87/100 (B+) | 86/100 (B) |
| Semaglutide | $179/mo | $189/mo |
| Tirzepatide | $239/mo | $349/mo |
| Coverage | All 50 states | Not publicly listed |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
Vaylen: $179 sema / $239 tirz; brand + oral + LegitScript across all 50 states.
HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.